Gerald DeNardo

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Chemicals & Drugs

Living Beings

Disorders

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
DeNardo G L; Mirick G R; Hok S; DeNardo S J; Beckett L A; Adamson G N; Balhorn R L
Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia.
Natarajan Arutselvan; Kumaresan Pappanaicken R; Denardo Sally J; Denardo Gerald L; Mirick Gary; Lam Kit S
Development of TNKase-specific cleavable peptide-linked radioimmunoconjugates for radioimmunotherapy.
DeNardo Gerald L; DeNardo Sally J; Balhorn Rod
Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Gerald DeNardo (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: DeNardo G L; Mirick G R; Hok S; DeNardo S J; Beckett L A; Adamson G N; Balhorn R L
Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia.
International journal of oncology 2009;34(2):511-6.
2008: Natarajan Arutselvan; Kumaresan Pappanaicken R; Denardo Sally J; Denardo Gerald L; Mirick Gary; Lam Kit S
Development of TNKase-specific cleavable peptide-linked radioimmunoconjugates for radioimmunotherapy.
Bioorganic & medicinal chemistry letters 2008;18(17):4802-5.
2008: DeNardo Gerald L; DeNardo Sally J; Balhorn Rod
Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?
Cancer biotherapy & radiopharmaceuticals 2008;23(4):383-97.
2008: Natarajan A; Gruettner C; Ivkov R; DeNardo G L; Mirick G; Yuan A; Foreman A; DeNardo S J
NanoFerrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics.
Bioconjugate chemistry 2008;19(6):1211-8.
2008: Lehmann Joerg; Natarajan Arutselvan; Denardo Gerald L; Ivkov Robert; Foreman Allan R; Catapano Christopher; Mirick Gary; Quang Tony; Gruettner Cordula; Denardo Sally J
Short communication: nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cells.
Cancer biotherapy & radiopharmaceuticals 2008;23(2):265-71.
2008: Natarajan Arutselvan; Xiong Cheng-Yi; Gruettner Cordula; DeNardo Gerald L; DeNardo Sally J
Development of multivalent radioimmunonanoparticles for cancer imaging and therapy.
Cancer biotherapy & radiopharmaceuticals 2008;23(1):82-91.
2007: DeNardo Gerald L
The conundrum of personalized cancer management, drug development, and economics.
Cancer biotherapy & radiopharmaceuticals 2007;22(6):719-21.
2007: Albrecht H; Denardo G L; Denardo S J
Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2007;51(4):304-13.
2007: DeNardo Gerald L; Hok Saphon; Van Natarajan Arutselvan; Cosman Monique; DeNardo Sally J; Lightstone Felice C; Mirick Gary R; Yuan Aina; Perkins Julie; Sysko Vladimir V; Lehmann Joerg; Balhorn Rodney L
Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma.
International journal of oncology 2007;31(4):729-40.
2007: Balhorn Rod; Hok Saphon; Burke Patricia A; Lightstone Felice C; Cosman Monique; Zemla Adam; Mirick Gary; Perkins Julie; Natarajan Arutselvan; Corzett Michele; DeNardo Sally J; Albrecht Huguette; Gregg Jeff P; DeNardo Gerry L
Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 2):5621s-5628s.
2007: Siantar Christine L Hartmann; DeNardo Gerald L; Lam Kit; Yuan Aina; Daly Thomas; DeNardo Sally J
Selecting an intervention time for intravascular enzymatic cleavage of peptide linkers to clear radioisotope from normal tissues.
Cancer biotherapy & radiopharmaceuticals 2007;22(4):556-63.
2007: Albrecht Huguette; Cosman Monique; Ngu-Schwemlein Maria; Corzett Michele; Curran Kena W; Dolan Cheryl; Fang Xiangming; DeNardo Sally J; DeNardo Gerald L; Balhorn Rod
Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules.
Cancer biotherapy & radiopharmaceuticals 2007;22(4):531-42.
2007: DeNardo Gerald L; Natarajan Arutselvan; Hok Saphon; Perkins Julie; Cosman Monique; DeNardo Sally J; Lightstone Felice C; Mirick Gary R; Miers Laird A; Balhorn Rodney L
Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2007;48(8):1338-47.
2007: Tobin Evan; Denardo Gerald; Zhang Nan; Epstein Alan L; Liu Cathy; Denardo Sally
Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines.
Leukemia & lymphoma 2007;48(5):944-56.
2007: Hok Saphon; Natarajan Arutselvan; Balhorn Rod; DeNardo Sally J; DeNardo Gerald L; Perkins Julie
Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia.
Bioconjugate chemistry 2007;18(3):912-21.
2007: DeNardo Sally J; DeNardo Gerald L; Natarajan Arutselvan; Miers Laird A; Foreman Allan R; Gruettner Cordula; Adamson Grete N; Ivkov Robert
Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF--induced thermoablative therapy for human breast cancer in mice.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2007;48(3):437-44.
2007: Natarajan Arutselvan; Du Wenjun; Xiong Cheng-Yi; DeNardo Gerald L; DeNardo Sally J; Gervay-Hague Jacquelyn
Construction of di-scFv through a trivalent alkyne-azide 1,3-dipolar cycloaddition.
Chemical communications (Cambridge, England) 2007;(7):695-7.
2007: Liu Hao; Beckett Laurel A; DeNardo Gerald L
On the analysis of count data of birth-and-death process type: with application to molecularly targeted cancer therapy.
Statistics in medicine 2007;26(5):1114-35.
2006: West Jeremy; Perkins Julie; Hok Saphon; Balhorn Rodney; Lightstone Felice C; Cosman Monique; DeNardo Sally J; DeNardo Gerald L
Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells.
Cancer biotherapy & radiopharmaceuticals 2006;21(6):645-54.
2006: Azinovic Ignacio; DeNardo Gerald L; Lamborn Kathleen R; Mirick Gary; Goldstein Desiree; Bradt Bonnie M; DeNardo Sally J
Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies.
Cancer immunology, immunotherapy : CII 2006;55(12):1451-8.
2006: Lehmann Joerg; DeNardo Gerald L; Yuan Aina; Shen Sui; O'Donnell Robert T; Richman Carol M; DeNardo Sally J
Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.
International journal of radiation oncology, biology, physics 2006;66(4):1192-8.
2006: Xiong Cheng-Yi; Natarajan Arutselvan; Shi Xu-Bao; Denardo Gerald L; Denardo Sally J
Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding.
Protein engineering, design & selection : PEDS 2006;19(8):359-67.
2006: Burke Patricia A; Gregg Jeffrey P; Bakhtiar Brandon; Beckett Laurel A; Denardo Gerald L; Albrecht Huguette; De Vere White Ralph W; De Nardo Sally J
Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules.
International journal of oncology 2006;29(1):49-55.
2006: Albrecht Huguette; Denardo Gerald L; Denardo Sally J
Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.
Journal of immunological methods 2006;310(1-2):100-16.
2005: Shen Sui; DeNardo Gerald L; Yuan Aina; Hartmann-Siantar Christine; O'Donnell Robert T; DeNardo Sally J
Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.
Cancer biotherapy & radiopharmaceuticals 2005;20(6):662-70.
2005: Miers Laird; DeNardo Sally J; Lamborn Kathleen; DeNardo Gerald L
Implantation of different malignant human cell lines in an athymic mouse does not alter success and growth rates of either xenograft.
Cancer biotherapy & radiopharmaceuticals 2005;20(6):614-9.
2005: DeNardo Sally J; Richman Carol M; Albrecht Huguette; Burke Patricia A; Natarajan Arut; Yuan Aina; Gregg Jeff P; O'Donnell R T; DeNardo Gerald L
Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 2):7187s-7194s.
2005: Miers Laird; Lamborn Kathleen; Yuan Aina; Richman Carol; Natarajan Arutselvan; DeNardo Sally; DeNardo Gerald
Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers?
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 2):7158s-7163s.
2005: Ivkov Robert; DeNardo Sally J; Daum Wolfgang; Foreman Allan R; Goldstein Robert C; Nemkov Valentin S; DeNardo Gerald L
Application of high amplitude alternating magnetic fields for heat induction of nanoparticles localized in cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 2):7093s-7103s.
2005: DeNardo Sally J; DeNardo Gerald L; Miers Laird A; Natarajan Arutselvan; Foreman Alan R; Gruettner Cordula; Adamson Grete N; Ivkov Robert
Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 2):7087s-7092s.
2005: DeNardo Gerald L; Tobin Evan; Chan Kaylund; Bradt Bonnie M; DeNardo Sally J
Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 2):7075s-7079s.
2005: Richman Carol M; Denardo Sally J; O'Donnell Robert T; Yuan Aina; Shen Sui; Goldstein Desiree S; Tuscano Joseph M; Wun Ted; Chew Helen K; Lara Primo N; Kukis David L; Natarajan Arutselvan; Meares Claude F; Lamborn Kathleen R; DeNardo Gerald L
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5920-7.
2005: Shen Sui; DeNardo Sally J; Richman Carol M; Yuan Aina; Siantar Christine Hartmann; O'Donnell Robert T; Kroger Linda A; DeNardo Gerald L
Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(6):1034-41.
2005: Lehmann Joerg; Hartmann Siantar Christine; Wessol Daniel E; Wemple Charles A; Nigg David; Cogliati Josh; Daly Tom; Descalle Marie-Anne; Flickinger Terry; Pletcher David; Denardo Gerald
Monte Carlo treatment planning for molecular targeted radiotherapy within the MINERVA system.
Physics in medicine and biology 2005;50(5):947-58.
2005: DeNardo Gerald L
Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective.
Seminars in oncology 2005;32(1 Suppl 1):S27-35.
2005: Natarajan Arutselvan; Xiong Cheng-Yi; Albrecht Huguette; DeNardo Gerald L; DeNardo Sally J
Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals.
Bioconjugate chemistry 2005;16(1):113-21.
2004: Mirick G R; Bradt B M; Denardo S J; Denardo G L
A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2004;48(4):251-7.
2004: Liu Cathy; DeNardo Gerald; Tobin Evan; DeNardo Sally
Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Cancer biotherapy & radiopharmaceuticals 2004;19(5):545-61.
2004: DeNardo Gerald L; DeNardo Sally J
Evaluation of a cathepsin-cleavable peptide linked radioimmunoconjugate of a panadenocarcinoma MAb, m170, in mice and patients.
Cancer biotherapy & radiopharmaceuticals 2004;19(1):85-92.
2004: Albrecht Huguette; Burke Patricia A; Natarajan Arutselvan; Xiong Cheng-Yi; Kalicinsky Mark; DeNardo Gerald L; DeNardo Sally J
Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand.
Bioconjugate chemistry 2004;15(1):16-26.
2003: DeNardo Gerald L; Mirick Gary R; Kroger Linda A; Bradt Bonnie M; Lamborn Kathleen R; DeNardo Sally J
Characterization of human IgG antimouse antibody in patients with B-cell malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 2):4013S-21S.
2003: Bradt Bonnie M; DeNardo Sally J; Mirick Gary R; DeNardo Gerald L
Documentation of idiotypic cascade after Lym-1 radioimmunotherapy in a patient with non-Hodgkin's lymphoma: basis for extended survival?
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 2):4007S-12S.
2003: DeNardo Sally J; DeNardo Gerald L; Yuan A; Richman Carol M; O'Donnell Robert T; Lara Primo N; Kukis David L; Natarajan Arutselvan; Lamborn Kathleen R; Jacobs Frederik; Siantar Christine L Hartmann
Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 2):3938S-44S.
2003: DeNardo Gerald L; DeNardo Sally J; Peterson James J; Miers Laird A; Lam Kit S; Hartmann-Siantar Christine; Lamborn Kathleen R
Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 2):3865S-72S.
2003: DeNardo Sally J; Yao Zhengsheng; Lam Kit S; Song Aimin; Burke Patricia A; Mirick Gary R; Lamborn Kathleen R; O'Donnell Robert T; DeNardo Gerald L
Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 2):3854S-64S.
2003: Winthrop Michelle D; DeNardo Sally J; Albrecht Huguette; Mirick Gary R; Kroger Linda A; Lamborn Kathleen R; Venclovas Ceslovas; Colvin Michael E; Burke Patricia A; DeNardo Gerald L
Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 2):3845S-53S.
2003: Hartmann Siantar Christine L; DeNardo Gerald L; DeNardo Sally J
Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(8):1322-9.
2003: DeNardo Gerald L; Bradt Bonnie M; Mirick Gary R; DeNardo Sally J
Human antiglobulin response to foreign antibodies: therapeutic benefit?
Cancer immunology, immunotherapy : CII 2003;52(5):309-16.
2003: Tuscano Joseph M; O'Donnell Robert T; Miers Laird A; Kroger Linda A; Kukis David L; Lamborn Kathleen R; Tedder Thomas F; DeNardo Gerald L
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
Blood 2003;101(9):3641-7.
2003: DeNardo Gerald; Yuan Aina; Goldstein Desiree; Richman Carol; O'Donnell Robert; Shen Sui; Hartmann Siantar Christine; DeNardo Sally
Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.
Cancer biotherapy & radiopharmaceuticals 2003;18(2):231-7.
2003: Descalle Marie-Anne; Hartmann Siantar Christine L; Dauffy Lucile; Nigg David W; Wemple Charles A; Yuan Aina; DeNardo Gerald L
Application of MINERVA Monte Carlo simulations to targeted radionuclide therapy.
Cancer biotherapy & radiopharmaceuticals 2003;18(1):71-9.
2002: Burke Patricia A; DeNardo Sally J; Miers Laird A; Lamborn Kathleen R; Matzku Siegfried; DeNardo Gerald L
Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
Cancer research 2002;62(15):4263-72.
2002: Siantar Christine Hartmann; Vetter Kai; DeNardo Gerald L; DeNardo Sally J
Treatment planning for molecular targeted radionuclide therapy.
Cancer biotherapy & radiopharmaceuticals 2002;17(3):267-80.
2002: DeNardo Gerald L; Siantar Christine L Hartmann; DeNardo Sally J
Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy.
Cancer biotherapy & radiopharmaceuticals 2002;17(1):107-18.
2002: DeNardo Gerald L; Schlom Jeffery; Buchsbaum Donald J; Meredith Ruby F; O'Donoghue Joseph A; Sgouros George; Humm John L; DeNardo Sally J
Rationales, evidence, and design considerations for fractionated radioimmunotherapy.
Cancer 2002;94(4 Suppl):1332-48.
2002: Burke Patricia A; DeNardo Sally J; Miers Laird A; Kukis David L; DeNardo Gerald L
Combined modality radioimmunotherapy. Promise and peril.
Cancer 2002;94(4 Suppl):1320-31.
2002: O'Donnell Robert T; DeNardo Sally J; Miers Laird A; Lamborn Kathleen R; Kukis David L; DeNardo Gerald L; Meyers Frederick J
Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
The Prostate 2002;50(1):27-37.
2001: DeNardo D G; Xiong C Y; Shi X B; DeNardo G L; DeNardo S J
Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy.
Cancer biotherapy & radiopharmaceuticals 2001;16(6):525-35.
2001: DeNardo G L; DeNardo S J; Kukis D L; O'Donnell R T; Shen S; Mirick G R; Meares C F
Metabolite production in patients with lymphoma after radiometal-labeled antibody administration.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2001;42(9):1324-33.
2001: Kroger L A; DeNardo G L; Gumerlock P H; Xiong C Y; Winthrop M D; Shi X B; Mack P C; Leshchinsky T; DeNardo S J
Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy.
Cancer biotherapy & radiopharmaceuticals 2001;16(3):213-25.
2001: O'Donnell R T; DeNardo S J; Yuan A; Shen S; Richman C M; Lara P N; Griffith I J; Goldstein D S; Kukis D L; Martinez G S; Mirick G R; DeNardo G L; Meyers F J
Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1561-8.
2000: DeNardo G L; DeNardo S J; Wessels B W; Kukis D L; Miyao N; Yuan A
131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis.
Cancer biotherapy & radiopharmaceuticals 2000;15(6):547-60.
2000: O'Donnell R T; Shen S; Denardo S J; Wun T; Kukis D L; Goldstein D S; Denardo G L
A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
Anticancer research 2000;20(5C):3647-55.
2000: Winthrop M D; Denardo G L; Denardo S J
Antibody phage display applications for nuclear medicine imaging and therapy.
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR) 2000;44(3):284-95.
2000: O'Donnell R T; DeNardo S J; DeNardo G L; Miers L; Lamborn K R; Kukis D L; Meyers F J
Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice.
The Prostate 2000;44(3):187-92.
2000: DeNardo G L; O'Donnell R T; Shen S; Kroger L A; Yuan A; Meares C F; Kukis D L; DeNardo S J
Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000;41(5):952-8.
2000: DeNardo S J; Burke P A; Leigh B R; O'Donnell R T; Miers L A; Kroger L A; Goodman S L; Matzku S; Jonczyk A; Lamborn K R; DeNardo G L
Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy.
Cancer biotherapy & radiopharmaceuticals 2000;15(1):71-9.
1999: Shen S; DeNardo G L; Sgouros G; O'Donnell R T; DeNardo S J
Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(12):2102-6.
1999: O'Donnell R T; DeNardo G L; Kukis D L; Lamborn K R; Shen S; Yuan A; Goldstein D S; Carr C E; Mirick G R; DeNardo S J
A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(12):2014-20.
1999: Kukis D L; DeNardo S J; Mills S L; Shen S; O'Donnell R T; DeNardo G L
Stability of monoclonal antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 immunoconjugate with ultra freezer storage.
Cancer biotherapy & radiopharmaceuticals 1999;14(5):363-9.
1999: Mirick G R; O'Donnell R T; DeNardo S J; Shen S; Meares C F; DeNardo G L
Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients.
Nuclear medicine and biology 1999;26(7):841-5.
1999: O'Donnell R T; DeNardo G L; Kukis D L; Lamborn K R; Shen S; Yuan A; Goldstein D S; Mirick G R; DeNardo S J
67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3330s-3336s.
1999: Richman C M; DeNardo S J; O'Donnell R T; Goldstein D S; Shen S; Kukis D L; Kroger L A; Yuan A; Boniface G R; Griffith I J; DeNardo G L
Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3243s-3248s.
1999: DeNardo G L; O'Donnell R T; Kroger L A; Richman C M; Goldstein D S; Shen S; DeNardo S J
Strategies for developing effective radioimmunotherapy for solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3219s-3223s.
1999: DeNardo S J; DeNardo G L; DeNardo D G; Xiong C Y; Shi X B; Winthrop M D; Kroger L A; Carter P
Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3213s-3218s.
1999: Winthrop M D; DeNardo S J; DeNardo G L
Development of a hyperimmune anti-MUC-1 single chain antibody fragments phage display library for targeting breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3088s-3094s.
1999: Kroger L A; DeNardo S J; DeNardo G L; Xiong C Y; Winthrop M D; Gumerlock P H
Effect of 67Cu-2IT-BAT-Lym-1 therapy on BCL-2 gene and protein expression in a lymphoma mouse model.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3010s-3014s.
1999: DeNardo G L
Tribute to David A. Goodwin and Claude F. Meares, recipients of the Immunomedics Science Award.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):2992s-2993s.
1999: Macey D J; DeNardo G L; DeNardo S J
Planar gamma camera quantitation of 123I, 99mTc or 111In in the liver and spleen of an abdominal phantom.
Cancer biotherapy & radiopharmaceuticals 1999;14(4):299-306.
1999: Rose L M; Deng C T; Scott S L; Xiong C Y; Lamborn K R; Gumerlock P H; DeNardo G L; Meares C F
Critical Lym-1 binding residues on polymorphic HLA-DR molecules.
Molecular immunology 1999;36(11-12):789-97.
1999: DeNardo G L; DeNardo S J; Shen S; DeNardo D A; Mirick G R; Macey D J; Lamborn K R
Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(8):1317-26.
1999: O'Donnell R T; Leigh B R; Christensen S D; Goldstein D S; Kukis D L; Shen S; Yuan A; DeNardo D A; Kroger L A; DeNardo G L
Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.
Cancer biotherapy & radiopharmaceuticals 1999;14(3):167-76.
1999: Shi X B; Gumerlock P H; Kroger L; DeNardo G L; DeNardo S J
Efficient recombination of Lym-1 scFv gene using multiple doubly-restricted DNA fragments.
Cancer biotherapy & radiopharmaceuticals 1999;14(2):139-43.
1999: Leigh B R; Burke P A; Hong A M; O'Donnell R T; Howell L P; Miers L A; DeNardo G L; DeNardo S J
Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy.
Cancer biotherapy & radiopharmaceuticals 1999;14(2):113-9.
1999: DeNardo G L; Kukis D L; Shen S; DeNardo D A; Meares C F; DeNardo S J
67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(3):533-41.
1999: DeNardo S J; DeNardo G L; Brush J; Carter P
Phage library-derived human anti-TETA and anti-DOTA ScFv for pretargeting RIT.
Hybridoma 1999;18(1):13-21.
1999: DeNardo G L; O'Donnell R T; Rose L M; Mirick G R; Kroger L A; DeNardo S J
Milestones in the development of Lym-1 therapy.
Hybridoma 1999;18(1):1-11.
1999: DeNardo S J; DeNardo G L; Kukis D L; Shen S; Kroger L A; DeNardo D A; Goldstein D S; Mirick G R; Salako Q; Mausner L F; Srivastava S C; Meares C F
67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(2):302-10.
1998: Kukis D L; DeNardo S J; DeNardo G L; O'Donnell R T; Meares C F
Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(12):2105-10.
1998: Denardo S J; Richman C M; Kukis D L; Shen S; Lamborn K R; Miers L A; Kroger L A; Perez E A; Denardo G L
Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.
Anticancer research 1998;18(6A):4011-8.
1998: O'Donnell R T; DeNardo S J; Miers L A; Kukis D L; Mirick G R; Kroger L A; DeNardo G L
Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
Cancer biotherapy & radiopharmaceuticals 1998;13(5):351-61.
1998: DeNardo G L; Kroger L A; Meares C F; Richman C M; Salako Q; Shen S; Lamborn K R; Peterson J J; Miers L A; Zhong G R; DeNardo S J
Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2483-90.
1998: DeNardo G L; DeNardo S J; Goldstein D S; Kroger L A; Lamborn K R; Levy N B; McGahan J P; Salako Q; Shen S; Lewis J P
Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3246-56.
1998: O'Donnell R T; DeNardo S J; Shi X B; Mirick G R; DeNardo G L; Kroger L A; Meyers F J
L6 monoclonal antibody binds prostate cancer.
The Prostate 1998;37(2):91-7.
1998: DeNardo G L; DeNardo S J; Lamborn K R; Goldstein D S; Levy N B; Lewis J P; O'Grady L F; Raventos A; Kroger L A; Macey D J; McGahan J P; Mills S L; Shen S
Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.
Cancer biotherapy & radiopharmaceuticals 1998;13(4):239-54.
1998: Denardo G L; Denardo S J; Kukis D L; O'Donnell R T; Shen S; Goldstein D S; Kroger L A; Salako Q; Denardo D A; Mirick G R; Mausner L F; Srivastava S C; Meares C F
Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
Anticancer research 1998;18(4B):2779-88.
1998: DeNardo S J; Kukis D L; Miers L A; Winthrop M D; Kroger L A; Salako Q; Shen S; Lamborn K R; Gumerlock P H; Meares C F; DeNardo G L
Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(5):842-9.
1998: DeNardo G L; Shen S; DeNardo S J; Liao S Q; Lamborn K R; DeNardo D A; Yuan A
Quantification of iodine-131 in tumors using a threshold based on image contrast.
European journal of nuclear medicine 1998;25(5):497-502.
1998: Feng X; Pak R H; Kroger L A; Moran J K; DeNardo D G; Meares C F; DeNardo G L; DeNardo S J
New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor.
Hybridoma 1998;17(2):125-32.
1998: DeNardo S J; Kroger L A; MacKenzie M R; Mirick G R; Shen S; DeNardo G L
Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody.
Cancer biotherapy & radiopharmaceuticals 1998;13(1):1-12.
1997: Richman C M; Schuermann T C; Wun T; Malik R; O'Donnell R T; DeNardo G L; DeNardo S J
Peripheral blood stem cell mobilization for hematopoietic support of radioimmunotherapy in patients with breast carcinoma.
Cancer 1997;80(12 Suppl):2728-32.
1997: DeNardo G L; Lamborn K R; Goldstein D S; Kroger L A; DeNardo S J
Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Cancer 1997;80(12 Suppl):2706-11.
1997: DeNardo S J; Kroger L A; Lamborn K R; Miers L A; O'Donnell R T; Kukis D L; Richman C M; DeNardo G L
Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma.
Cancer 1997;80(12 Suppl):2583-90.
1997: DeNardo G L; Kukis D L; DeNardo S J; Shen S; Mausner L F; O'Donnell R T; Lamborn K R; Meyers F J; Srivastava S C; Miers L A
Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2.
Cancer 1997;80(12 Suppl):2576-82.
1997: DeNardo D A; DeNardo G L; O'Donnell R T; Lim S M; Shen S; Yuan A; DeNardo S J
Imaging for improved prediction of myelotoxicity after radioimmunotherapy.
Cancer 1997;80(12 Suppl):2558-66.
1997: Shen S; DeNardo G L; O'Donnell R T; Yuan A; DeNardo D A; DeNardo S J
Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies.
Cancer 1997;80(12 Suppl):2553-7.
1997: DeNardo G L
Tribute to Ralph A. Reisfeld, Ph.D.
Cancer 1997;80(12 Suppl):2345-6.
1997: Lim S; DeNardo G L; DeNardo D A; O'Donnell R T; Yuan A; DeNardo S J
Prediction of myelotoxicity using semi-quantitative marrow image scores.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1997;38(11):1749-53.
1997: Lim S M; DeNardo G L; DeNardo D A; Shen S; Yuan A; O'Donnell R T; DeNardo S J
Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1997;38(9):1374-8.
1997: DeNardo S J; Kramer E L; O'Donnell R T; Richman C M; Salako Q A; Shen S; Noz M; Glenn S D; Ceriani R L; DeNardo G L
Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1997;38(8):1180-5.
1997: Shen S; DeNardo G L; Macey D J; O'Donnell R T; Yuan A; DeNardo D A; DeNardo S J
Practical determination of organ S values for individual patients for therapy.
Nuclear medicine and biology 1997;24(5):447-9.
1997: Denardo S J; O'Grady L F; Richman C M; Goldstein D S; O'Donnell R T; Denardo D A; Kroger L A; Lamborn K R; Hellström K E; Hellström I; Denardo G L
Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody.
Anticancer research 1997;17(3B):1745-51.
1997: Denardo S J; Richman C M; Goldstein D S; Shen S; Salako Q; Kukis D L; Meares C F; Yuan A; Welborn J L; Denardo G L
Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
Anticancer research 1997;17(3B):1735-44.
1997: Morris G; DeNardo S J; DeNardo G L; Leshchinsky T; Wu B; Mack P C; Winthrop M D; Gumerlock P H
Decreased C-MYC and BCL2 expression correlates with methylprednisolone-mediated inhibition of Raji lymphoma growth.
Biochemical and molecular medicine 1997;60(2):108-15.
1997: DeNardo S J; Kukis D L; Kroger L A; O'Donnell R T; Lamborn K R; Miers L A; DeNardo D G; Meares C F; DeNardo G L
Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(8):4000-4.
1997: DeNardo G L; Kukis D L; Shen S; Mausner L F; Meares C F; Srivastava S C; Miers L A; DeNardo S J
Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji).
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(1):71-9.
1997: Shen S; DeNardo G L; DeNardo S J; Yuan A; DeNardo D A; Lamborn K R
Reproducibility of operator processing for radiation dosimetry.
Nuclear medicine and biology 1997;24(1):77-83.
1996: DeNardo D A; DeNardo G L; Yuan A; Shen S; DeNardo S J; Macey D J; Lamborn K R; Mahe M; Groch M W; Erwin W D
Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996;37(12):1970-5.
1996: Rose L M; Gunasekera A H; DeNardo S J; DeNardo G L; Meares C F
Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10.
Cancer immunology, immunotherapy : CII 1996;43(1):26-30.
1996: Wilder R B; DeNardo G L; Sheri S; Fowler J F; Wessels B W; DeNardo S J
Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy.
European journal of nuclear medicine 1996;23(8):953-7.
1996: Erwin W D; Groch M W; Macey D J; DeNardo G L; DeNardo S J; Shen S
A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy.
Nuclear medicine and biology 1996;23(4):525-32.
1996: Wilder R B; DeNardo G L; DeNardo S J
Radioimmunotherapy: recent results and future directions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1383-400.
1996: DeNardo G L; Mirick G R; Kroger L A; O'Donnell R T; Meares C F; DeNardo S J
Antibody responses to macrocycles in lymphoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996;37(3):451-6.
1996: DeNardo G L; Kukis D L; Shen S; DeNardo S J
Accurate measurement of copper-67 in the presence of copper-64 contaminant using a dose calibrator.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996;37(2):302-6.
1996: Shen S; DeNardo G L; DeNardo S J; Salako Q; Morris G; Banks D; Yuan A; DeNardo D A
Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996;37(1):146-50.
1995: Richman C M; DeNardo S J; O'Grady L F; DeNardo G L
Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions.
Cancer research 1995;55(23 Suppl):5916s-5920s.
1995: DeNardo G L; Lamborn K R; DeNardo S J; Goldstein D S; Dolber-Smith E G; Kroger L A; Larkin E C; Shen S
Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies.
Cancer research 1995;55(23 Suppl):5893s-5898s.
1995: DeNardo S J; Gumerlock P H; Winthrop M D; Mack P C; Chi S G; Lamborn K R; Shen S; Miers L A; deVere White R W; DeNardo G L
Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression.
Cancer research 1995;55(23 Suppl):5837s-5841s.
1995: DeNardo S J; Zhong G R; Salako Q; Li M; DeNardo G L; Meares C F
Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1995;36(5):829-36.
1995: Lewis J P; Denardo G L; Denardo S J
Radioimmunotherapy of lymphoma: a UC Davis experience.
Hybridoma 1995;14(2):115-20.
1995: Kukis D L; DeNardo G L; DeNardo S J; Mirick G R; Miers L A; Greiner D P; Meares C F
Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates.
Cancer research 1995;55(4):878-84.
1995: Macey D J; DeNardo S J; DeNardo G L; DeNardo D A; Shen S
Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy.
Clinical nuclear medicine 1995;20(2):117-25.
1994: Shen S; DeNardo G L; DeNardo S J
Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter.
Medical physics 1994;21(9):1409-17.
1994: Shen S; DeNardo G L; Yuan A; DeNardo D A; DeNardo S J
Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1994;35(8):1381-9.
1994: DeNardo G L; Lewis J P; DeNardo S J; O'Grady L F
Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia.
Cancer 1994;73(5):1425-32.
1994: Kukis D L; Diril H; Greiner D P; DeNardo S J; DeNardo G L; Salako Q A; Meares C F
A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates.
Cancer 1994;73(3 Suppl):779-86.
1994: DeNardo G L; DeNardo S J; Macey D J; Shen S; Kroger L A
Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model.
Cancer 1994;73(3 Suppl):1038-48.
1994: DeNardo S J; Mirick G R; Kroger L A; O'Grady L F; Erickson K L; Yuan A; Lamborn K R; Hellstrom I; Hellstrom K E; DeNardo G L
The biologic window for chimeric L6 radioimmunotherapy.
Cancer 1994;73(3 Suppl):1023-32.
1994: DeNardo G L; Kroger L A; DeNardo S J; Miers L A; Salako Q; Kukis D L; Fand I; Shen S; Renn O; Meares C F
Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3).
Cancer 1994;73(3 Suppl):1012-22.
1994: DeNardo G L; Lamborn K R; DeNardo S J; Kroger L A
Use of response surface statistical designs to detect effects of biologic response modifiers such as IL-2.
Biotechnology therapeutics 1994;5(1-2):15-26.
1994: DeNardo S J; O'Grady L F; Richman C M; DeNardo G L
Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6.
Advances in experimental medicine and biology 1994;353():203-11.
1993: Shi X B; Gumerlock P H; Wellman A A; Meares C F; DeNardo G L; Meyers F J; DeNardo S J
Rapid PCR construction of a gene containing Lym-1 antibody variable regions.
PCR methods and applications 1993;3(1):46-53.
1993: DeNardo G L; Mahe M A; DeNardo S J; Macey D J; Mirick G R; Erwin W D; Groch M W
Body and blood clearance and marrow radiation dose of 131I-Lym-1 in patients with B-cell malignancies.
Nuclear medicine communications 1993;14(7):587-95.
1993: Kramer E L; DeNardo S J; Liebes L; Kroger L A; Noz M E; Mizrachi H; Salako Q A; Furmanski P; Glenn S D; DeNardo G L
Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1993;34(7):1067-74.
1991: DeNardo S J; Warhoe K A; O'Grady L F; Hellstrom I; Hellstrom K E; Mills S L; Macey D J; Goodnight J E; DeNardo G L
Radioimmunotherapy for breast cancer: treatment of a patient with I-131 L6 chimeric monoclonal antibody.
The International journal of biological markers 1991;6(4):221-30.
1991: DeNardo G; DeNardo S; Kukis D; Diril H; Suey C; Meares C
Strategies for enhancement of radioimmunotherapy.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1991;18(6):633-40.
1991: DeNardo S J; O'Grady L F; Macey D J; Kroger L A; DeNardo G L; Lamborn K R; Levy N B; Mills S L; Hellstrom I; Hellstrom K E
Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1991;18(6):621-31.
1990: Deshpande S V; DeNardo S J; Kukis D L; Moi M K; McCall M J; DeNardo G L; Meares C F
Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1990;31(4):473-9.
1990: DeNardo G L; DeNardo S J; O'Grady L F; Levy N B; Adams G P; Mills S L
Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1.
Cancer research 1990;50(3 Suppl):1014s-1016s.
1990: Deshpande S V; Subramanian R; McCall M J; DeNardo S J; DeNardo G L; Meares C F
Metabolism of indium chelates attached to monoclonal antibody: minimal transchelation of indium from benzyl-EDTA chelate in vivo.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1990;31(2):218-24.
1990: DeNardo G L; DeNardo S J; O'Grady L F; Mills S L; Lewis J P; Macey D J
Radiation treatment of B cell malignancies with immunoconjugate.
Frontiers of radiation therapy and oncology 1990;24():194-201; discussion 202-3.
1990: DeNardo S J; Deshpande S V; Moi M K; Adamas G P; McCall M K; DeNardo G L; Meares C F
Today and tomorrow: radiochemistry for radioimmunotherapy of breast cancer.
Frontiers of radiation therapy and oncology 1990;24():142-50; discussion 161-5.
1990: Macey D J; DeNardo G L; DeNardo S J
A treatment planning program for radioimmunotherapy.
Frontiers of radiation therapy and oncology 1990;24():123-31; discussion 161-5.
1989: Adams G P; DeNardo S J; Deshpande S V; DeNardo G L; Meares C F; McCall M J; Epstein A L
Effect of mass of 111In-benzyl-EDTA monoclonal antibody on hepatic uptake and processing in mice.
Cancer research 1989;49(7):1707-11.
1989: DeNardo G L; Macey D J; DeNardo S J; Zhang C G; Custer T R
Quantitative SPECT of uptake of monoclonal antibodies.
Seminars in nuclear medicine 1989;19(1):22-32.
1989: DeNardo S J; DeNardo G L; Peng J S
Pharmaceutical quality control of radiolabeled monoclonal antibodies and their fragments.
American journal of physiologic imaging 1989;4(1):39-44.
1989: Deshpande S V; Denardo S J; Meares C F; McCall M J; Adams G P; Denardo G L
Effect of different linkages between chelates and monoclonal antibodies on levels of radioactivity in the liver.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1989;16(6):587-97.
1988: Deshpande S V; DeNardo S J; Meares C F; McCall M J; Adams G P; Moi M K; DeNardo G L
Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1988;29(2):217-25.
1988: Macey D J; DeNardo G L; DeNardo S J
Comparison of three boundary detection methods for SPECT using Compton scattered photons.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1988;29(2):203-7.
1988: Macey D J; Denardo S J; Denardo G L; Goodnight J K; Unger M W
Uptake of indium-111-labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma.
American journal of physiologic imaging 1988;3(1):1-6.
1988: DeNardo S J; DeNardo G L; O'Grady L F; Hu E; Sytsma V M; Mills S L; Levy N B; Macey D J; Miller C H; Epstein A L
Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1988;3():96-101.
1987: Cole W C; DeNardo S J; Meares C F; McCall M J; DeNardo G L; Epstein A L; O'Brien H A; Moi M K
Comparative serum stability of radiochelates for antibody radiopharmaceuticals.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1987;28(1):83-90.
1987: DeNardo S J; DeNardo G L; O'Grady L F; Macey D J; Mills S L; Epstein A L; Peng J S; McGahan J P
Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies.
The International journal of biological markers 1987;2(1):49-53.
1986: Macey D J; DeNardo G L; DeNardo S J; Hines H H
Comparison of low- and medium-energy collimators for SPECT imaging with iodine-123-labeled antibodies.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1986;27(9):1467-74.
1986: Koizumi K; DeNardo G L; DeNardo S J; Hays M T; Hines H H; Scheibe P O; Peng J S; Macey D J; Tonami N; Hisada K
Multicompartmental analysis of the kinetics of radioiodinated monoclonal antibody in patients with cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1986;27(8):1243-54.
1986: Mills S L; Denardo S J; Denardo G L; Epstein A L; Peng J S; Colcher D
123I radiolabeling of monoclonal antibodies for in vivo procedures.
Hybridoma 1986;5(4):265-75.
1986: Cole W C; DeNardo S J; Meares C F; McCall M J; DeNardo G L; Epstein A L; O'Brien H A; Moi M K
Serum stability of 67Cu chelates: comparison with 111In and 57Co.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1986;13(4):363-8.
1986: DeNardo S J; Peng J S; DeNardo G L; Mills S L; Epstein A L
Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1986;13(4):303-10.
1986: O'Grady L F; DeNardo G; DeNardo S
Radiolabelled monoclonal antibodies for the detection of cancer.
American journal of physiologic imaging 1986;1(1):44-53.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Gerald DeNardo

Research Profile (preview)

Procedures

Chemicals & Drugs

Living Beings

Disorders

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Gerald DeNardo (preview)

All Publications